Key Summary:
- ctDNA positivity predicted shorter progression-free survival after SBRT.
- Six-month PFS was 21.1% with ctDNA positivity versus 58.3% without.
- ctDNA negativity may help identify patients who could benefit from SBRT.

ctDNA POSITIVITY before stereotactic body radiotherapy (SBRT) was associated with significantly shorter progression-free survival in patients with oligoprogressive metastatic castration-resistant prostate cancer, according to a prespecified secondary analysis of a prospective Phase 2 clinical trial.
The analysis included 77 patients with evaluable blood samples from the Targeted Radiotherapy in Androgen-Suppressed Prostate Cancer Patients trial. Patients had castration-resistant prostate cancer with two or fewer metastases showing progression while receiving an androgen receptor pathway inhibitor (ARPI).
SBRT was delivered to progressing metastases, with patients continuing ARPI treatment and undergoing clinical assessments, prostate-specific antigen testing and imaging. Blood samples collected before SBRT were analysed for circulating tumour DNA (ctDNA).
Before SBRT, 19 of 77 patients (24.7%) were ctDNA positive. Six-month progression-free survival was 21.1% (95% CI: 6.6%–41.0%) among ctDNA-positive patients compared with 58.3% (95% CI: 44.5%–69.8%) among ctDNA-negative patients.
Median progression-free survival was also shorter in the ctDNA-positive group, at 3.0 months (95% CI: 2.7–5.9), compared with 7.8 months (95% CI: 5.9–11.4) in the ctDNA-negative group (p=0.003).
The median time to initiation of a new therapy or death was 15.3 months (95% CI: 4.7–26.0) for ctDNA-positive patients and 29.6 months (95% CI: 17.8–37.6) for ctDNA-negative patients.
Median overall survival was 27.2 months (95% CI: 19.2–undefined) in the ctDNA-positive group and 33.6 months (95% CI: 28.4–38.2) in the ctDNA-negative group.
In conclusion, ctDNA positivity before SBRT is associated with significantly shorter progression-free survival in patients with oligoprogressive metastatic castration-resistant prostate cancer,
The findings suggested that pretreatment ctDNA status could help identify patients more likely to experience prolonged disease control following SBRT. Patients with oligoprogression and no detectable ctDNA may therefore represent a group in whom SBRT alongside continued ARPI treatment could be considered to prolong disease control.
The researchers concluded that ctDNA could have a role in selecting patients for SBRT, although the analysis was based on a nonrandomized clinical trial.
Reference
Reid A et al. Circulating tumor DNA in oligoprogressive prostate cancer treated with stereotactic radiotherapy: a prespecified secondary analysis of a nonrandomized clinical trial. JAMA Netw Open. 2026;9;(11):e2643400.
Featured image: ARMMY PICCA on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.